A proof-of-concept investigation into ketamine as a pharmacological treatment for alcohol dependence: study protocol for a randomised controlled trial

Amy McAndrew, Will Lawn, Tobias Stevens, Lilla Porffy, Brigitta Brandner, Celia J A Morgan, Amy McAndrew, Will Lawn, Tobias Stevens, Lilla Porffy, Brigitta Brandner, Celia J A Morgan

Abstract

Background: Worldwide, alcohol abuse is a burgeoning problem. Abstinence is key to allow recovery of physical and mental health as well as quality of life, but treatment for alcohol dependence is associated with high relapse rates. Preliminary data have suggested that a combined repeated ketamine and psychological therapy programme may be effective in reducing relapse in severe alcohol use disorder. This non-commercial proof-of-concept trial is aimed at making a preliminary assessment of the effectiveness of this combined treatment in this patient group.

Methods/design: This is a phase II, randomised, double-blind, placebo-controlled, parallel-group clinical trial taking place in two sites in the UK: the South West of England and London. Ninety-six recently detoxified alcoholics, with comorbid depressive symptoms, will be randomised to one of four treatment arms. Patients will receive either three sessions of ketamine (0.8 mg/kg administered intravenously (IV) over 40 minutes) or placebo (50 ml saline 0.9% IV over 40 minutes) plus either seven sessions of manualised psychological therapy or an alcohol education control. Patients will be assessed at 3 and 6 months on a range of psychological and biological variables. The primary endpoints are (1) relapse rates at 6 months and (2) percentage days abstinent at 6 months. Secondary endpoints include 3 and 6 month percentage days abstinence, tolerability (indicated by dropout), adverse events, depressive symptoms, craving and quality of life.

Discussion: This study will provide important information on a new combined psychological and pharmacological intervention aimed at reducing relapse rates in alcoholics. The findings would have broad application given the worldwide prevalence of alcoholism and its associated medical, psychological and social problems.

Trial registration: ClinicalTrials.gov, NCT02649231 . Registered on 5 January 2016.

Keywords: Alcoholism; Depression; Ketamine; Relapse.

Figures

Fig. 1
Fig. 1
KARE trial design. Step 1: Participants are initially identified and go through pre-screening. Step 2: If eligible, participants are invited for a screening visit to further determine eligibility. Step 3: If eligible, participants are randomised into one of four treatment conditions: (1) ketamine + relapse prevention therapy, (2) ketamine + alcohol education, (3) placebo + relapse prevention therapy, (4) placebo + alcohol education. Treatment runs over 7 sessions (1 therapy/education per session, ketamine/placebo is administered in 3 sessions). Step 4: Participants are followed up at 12 weeks. Step 5: Participants are followed up at 24 weeks
Fig. 2
Fig. 2
KARE trial SPIRIT checklist. This checklist contains all trial-specific assessments that will be run on each study visit. An ‘X’ denotes that this assessment will be run. * Physical examination: cardiovascular, respiratory, gastrointestinal and neurological assessment to a level of detail that would be expected for a patient due to receive anesthesia. ** Vital Signs: Resting pulse, pulse oximetry and blood pressure for safety monitoring. Vital signs will also be continuously monitored throughout the infusion until the participant has recovered. Xa Bloods: Full Blood Count (haemoglobin, white cell count, platelets, mean red cell volume); Liver Function Tests (Bilirubin, Alanine aminotransferase, Asparate aminotransferase, Total Protein, Alkaline phosphatase, Albumin, Globulin, gamma-glutamyl transpeptidase), Biochemistry (urea, sodium, potassium, glucose, calcium, thyroid stimulating hormone). Xb Bloods: Liver Function Tests (same as above); Brain-derived neurotrophic factor; ketamine. Xc Urine drug screen panel (methamphetamine, cocaine, tetrahydrocannabinol, benzodiazepines, tricyclic antidepressants, barbiturates, phencyclidine, amphetamines, morphine, methadone) including ketamine. Xd Urine drug screen panel (same as above) excluding ketamine

References

    1. World Health Organisation. Global status report on alcohol and health. 2011. .
    1. Health and Social Care Information Centre Statistics on Alcohol: England 2011; 2012. 2012. .
    1. Krupitsky EM, Grinenko AY. Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. J Psychoactive Drugs. 1997;29:165–83. doi: 10.1080/02791072.1997.10400185.
    1. Kolp E, Krupitsky E, Young MS, Jansen K, Friedman H, O’Connor LA. Ketamine-enhanced psychotherapy: preliminary clinical observations on its effects in treating death anxiety. Int J Transpersonal Stud. 2007;26:1–17.
    1. Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiat. 2006;638:856–64. doi: 10.1001/archpsyc.63.8.856.
    1. Aan Het Rot M, Zarate CA, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here? Biol Psychiat. 2012;72:537–47. doi: 10.1016/j.biopsych.2012.05.003.
    1. Sabino V, Narayan AR, Zeric T, Steardo L, Cottone P. mTOR activation is required for the anti-alcohol effect of ketamine, but not memantine, in alcohol-preferring rats. Behav Brain Res. 2013;247:9–16. doi: 10.1016/j.bbr.2013.02.030.
    1. Chambers R. Adult hippocampal neurogenesis in the pathogenesis of addiction and dual diagnosis disorders. Drug Alcohol Depen. 2013;130:1–12. doi: 10.1016/j.drugalcdep.2012.12.005.
    1. Mandyam CD, Koob GF. The addicted brain craves new neurons: putative role for adult-born progenitors in promoting recovery. Trends Neurosci. 2012;35:250–60. doi: 10.1016/j.tins.2011.12.005.
    1. Helfer JL, Goodlett CR, Greenough WT, Klintsova AY. The effects of exercise on adolescent hippocampal neurogenesis in a rat model of binge alcohol exposure during the brain growth spurt. Brain Res. 2009;1294:1–11. doi: 10.1016/j.brainres.2009.07.090.
    1. Hernandez-Rabaza V, Navarro-Mora G, Velazquez-Sanchez C, Ferragud A, Marin MP, Garcia-Verdugo JM, Renau-Piqueras J, Canales JJ. Neurotoxicity and persistent cognitive deficits induced by combined MDMA and alcohol exposure in adolescent rats. Addict Biol. 2010;15:413–23. doi: 10.1111/j.1369-1600.2010.00259.x.
    1. Nixon K, Kim DH, Potts EN, He J, Crews FT. Distinct cell proliferation events during abstinence after alcohol dependence: microglia proliferation precedes neurogenesis. Neurobiol Dis. 2008;31:218–29. doi: 10.1016/j.nbd.2008.04.009.
    1. Stevenson JR, Schroeder JP, Nixon K, Besheer J, Crews FT, Hodge CW. Abstinence following alcohol drinking produces depression-like behaviour and reduced hippocampal neurogenesis in mice. Neuropsychopharmacol. 2009;34:1209–22. doi: 10.1038/npp.2008.90.
    1. Nixon K, Crews FT. Temporally specific burst in cell proliferation increases hippocampal neurogenesis in protracted abstinence from alcohol. J Neurosci. 2004;24:9714–22. doi: 10.1523/JNEUROSCI.3063-04.2004.
    1. Crews FT, Nixon K, Wilkie ME. Exercise reverses ethanol inhibition of neural stem cell proliferation. Alcohol. 2004;33:63–71. doi: 10.1016/S0741-8329(04)00081-3.
    1. Zanardini R, Fontana A, Pagano R, Mazzaro E, Bergamasco F, Romagnosi G, Gennarelli M, Bocchio-Chiavetto L. Alterations of brain-derived neurotrophic factor serum levels in patients with alcohol dependence. Alcohol Clin Exp Res. 2011;35:1529–33.
    1. Herrera DG, Yagüe AG, Johnsen-Soriano S, Bosch-Morell F, Collado-Morente L, Muriach M, Romero FJ, García-verdugo JM. Selective impairment of hippocampal neurogenesis by chronic alcoholism: protective effects of an antioxidant. Proc Natl Acad Sci U S A. 2003;100:7919–24. doi: 10.1073/pnas.1230907100.
    1. Grosjean B. From synapse to psychotherapy: the fascinating evolution of neuroscience. Am J Psychother. 2005;59:181–97.
    1. Bates ME, Buckman JF, Nguyen TT. A role for cognitive rehabilitation in increasing the effectiveness of treatment for alcohol use disorders. Neuropsychol Rev. 2013;23:27–47. doi: 10.1007/s11065-013-9228-3.
    1. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959–64. doi: 10.1126/science.1190287.
    1. Krupitsky EM, Burakov AM, Romanova TN, Grinenko NI, Grinenko AY, Fletcher J, Petrakis IL, Krystal JH. Attenuation of ketamine effects by nimodipine pretreatment in recovering ethanol dependent men: psychopharmacologic implications of the interaction of NMDA and L-type calcium channel antagonists. Neuropsychopharmacol. 2001;25:936–47. doi: 10.1016/S0893-133X(01)00346-3.
    1. Birch AM, McGarry NB, Kelly AM. Short-term environment enrichment, in the absence of exercise, improves memory, and increases NGF concentration, early neuronal survival, and synaptogenesis in the dentate gyrus in a time-dependent manner. Hippocampus. 2013;23:437–50. doi: 10.1002/hipo.22103.
    1. Morgan CJ, Mofeez A, Brandner B, Bromley L, Curran HV. Ketamine impairs response inhibition and is positively reinforcing in healthy volunteers: a dose-response study. Psychopharmacology. 2004;172:298–308.
    1. Krystal JH, Petrakis IL, Webb E, Cooney NL, Karper LP, Namanworth S, Stetson P, Trevisan LA, Charney DS. Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Arch Gen Psychiat. 1998;55:354–60.
    1. Yale University. Ketamine for Depression and Alcohol Dependence (KetamineDep). In: . 2014. . Accessed 16 Sept 2016.
    1. Aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiat. 2010;67:139–45. doi: 10.1016/j.biopsych.2009.08.038.
    1. Linderfors N, Barati S, O’Connor WT. Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex. Brain Res. 1997;759:205–12. doi: 10.1016/S0006-8993(97)00255-2.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren